<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573725</url>
  </required_header>
  <id_info>
    <org_study_id>TS142-201</org_study_id>
    <nct_id>NCT04573725</nct_id>
  </id_info>
  <brief_title>Early Phase 2 Clinical Study of TS-142 in Patients With Insomnia Disorder</brief_title>
  <official_title>Early Phase 2 Clinical Study of TS-142 in Patients With Insomnia Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, randomized, placebo-controlled, 4-arm, 4-period crossover double-blind&#xD;
      comparative study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2017</start_date>
  <completion_date type="Actual">February 13, 2019</completion_date>
  <primary_completion_date type="Actual">February 13, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LS mean difference of LPS from placebo</measure>
    <time_frame>Day 1</time_frame>
    <description>LPS is defined as the duration of time from the light off to the first persistent (10 consecutive minutes) sleep episode as measured by overnight PSG.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LS mean difference of WASO from placebo</measure>
    <time_frame>Day 1</time_frame>
    <description>WASO is defined as the time spent in wakefulness from the first persistent (10 consecutive minutes) sleep episode to the light on as measured by overnight PSG.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LS mean difference of TST from placebo</measure>
    <time_frame>Day 1</time_frame>
    <description>TST is defined as the time spent in sleep from the light off to the light on as measured by overnight PSG.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Insomnia Disorder</condition>
  <arm_group>
    <arm_group_label>5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period in which participants received single-dose of 5 mg TS-142 prior to bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period in which participants received single-dose of 10 mg TS-142 prior to bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period in which participants received single-dose of 30 mg TS-142 prior to bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Period in which participants received single placebo prior to bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-142</intervention_name>
    <description>Participants received single-dose of 5, 10, 30 mg of TS-142 (oral capsule)</description>
    <arm_group_label>10 mg</arm_group_label>
    <arm_group_label>30 mg</arm_group_label>
    <arm_group_label>5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose-matched Placebo to TS-142</intervention_name>
    <description>Participants received single dose-matched placebo to TS-142 (oral capsule)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients&#xD;
&#xD;
          -  Patients diagnosed with insomnia disorder according to the Diagnostic and Statistical&#xD;
             Manual of Mental Disorders, Fifth Edition (DSM-5)&#xD;
&#xD;
          -  Patients who scored 15 or higher on the Insomnia Severity Index (ISI) at Visit 1&#xD;
&#xD;
          -  Other protocol defined inclusion criteria could apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of any of the following diseases according to the DSM-5&#xD;
             criteria:&#xD;
&#xD;
               1. Hypersomnolence disorder&#xD;
&#xD;
               2. Narcolepsy&#xD;
&#xD;
               3. Breathing-related sleep disorders&#xD;
&#xD;
               4. Circadian rhythm sleep-wake disorder&#xD;
&#xD;
               5. Parasomnias&#xD;
&#xD;
               6. Restless legs syndrome&#xD;
&#xD;
               7. Substance/medication-induced sleep disorder&#xD;
&#xD;
          -  Patients complicated with organic brain disease (including neurodegenerative disease,&#xD;
             cerebrovascular disorder), and/or epilepsy&#xD;
&#xD;
          -  Patients with a history of poorly controlled diabetes mellitus (HbA1c &gt;8%)&#xD;
&#xD;
          -  Patients with difficulty in sleeping due to medical problems such as pain, pruritus,&#xD;
             heart disease, nocturia (&gt;3 times per night), bronchial asthma, reflux oesophagitis,&#xD;
             endocrine disease, hot flush, and periodic limb movement disorder&#xD;
&#xD;
          -  Other protocol defined exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshiro Heya</last_name>
    <role>Study Director</role>
    <affiliation>Taisho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taisho Pharmaceutical Co., Ltd selected site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

